0001209191-17-057318.txt : 20171018 0001209191-17-057318.hdr.sgml : 20171018 20171018173428 ACCESSION NUMBER: 0001209191-17-057318 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20171016 FILED AS OF DATE: 20171018 DATE AS OF CHANGE: 20171018 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cantley Lewis Clayton Jr. CENTRAL INDEX KEY: 0001581950 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36014 FILM NUMBER: 171143263 MAIL ADDRESS: STREET 1: C/O AGIOS PHARMACEUTICALS, INC. STREET 2: 38 SIDNEY STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001439222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-8600 MAIL ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-10-16 0 0001439222 AGIOS PHARMACEUTICALS INC AGIO 0001581950 Cantley Lewis Clayton Jr. C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139 1 0 0 0 Common stock 2017-10-16 4 S 0 1000 71.09 D 84394 D Common stock 2017-10-16 4 S 0 1000 71.09 D 84434 I See footnote Common stock 2017-10-17 4 S 0 1000 71.10 D 83394 D Common stock 2017-10-17 4 S 0 1000 71.10 D 83434 I See footnote Common stock 20803 I See footnote Common stock 20803 I See footnote This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $70.58 to $71.83. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Shares held by Vicki Lee Sato, who is the reporting person's spouse. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $70.71 to $71.51. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Shares held by grantor retained annuity trusts for the benefit of the reporting person and his two children, of which the reporting person is trustee and sole annuitant. Shares held by grantor retained annuity trusts for the benefit of the reporting person's spouse and their two children, of which the reporting person's spouse is trustee and sole annuitant. /s/ William Cook, as Attorney-in-fact for Lewis C. Cantley Jr. 2017-10-18 EX-24 2 attachment1.htm EX-24 DOCUMENT

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

       Know all by these presents, that the undersigned hereby makes,
constitutes and appoints each of David P.
Schenkein, Andrew Hirsch, Min Wang and William Cook, signing singly and each
acting individually, as the
undersigned's true and lawful attorney-in-fact with full power and authority as
hereinafter described to:
       (1)	execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or
director of Agios Pharmaceuticals, Inc. (the ?Company?), Forms 3, 4, and 5
(including any amendments thereto)
in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder (the ?Exchange
Act?);
       (2)	do and perform any and all acts for and on behalf of the undersigned
which may be necessary or
desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare,
complete and execute any
amendment or amendments thereto, and timely deliver and file such form with the
United States Securities and
Exchange Commission (the ?SEC?) and any stock exchange or similar authority,
including without limitation the
filing of a Form ID or any other application materials to enable the undersigned
to gain or maintain access to the
Electronic Data Gathering, Analysis and Retrieval system of the SEC;
       (3)	seek or obtain, as the undersigned?s representative and on the
undersigned?s behalf, information
regarding transactions in the Company?s securities from any third party,
including brokers, employee benefit plan
administrators and trustees, and the undersigned hereby authorizes any such
person to release any such
information to such attorney-in-fact and approves and ratifies any such release
of information; and
       (4)	take any other action of any type whatsoever in connection with the
foregoing which, in the
opinion of such attorney-in-fact, may be of benefit to, in the best interest of,
or legally required by, the
undersigned, it being understood that the documents executed by such
attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions
as such attorney-in-fact may approve in such attorney-in-fact's discretion.
       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform
any and every act and thing whatsoever requisite, necessary, or proper to be
done in the exercise of any of the
rights and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if
personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue
of this power of attorney and the rights and powers herein granted.  The
undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming nor
relieving, nor is the Company assuming nor relieving, any of the undersigned's
responsibilities to comply with
Section 16 of the Exchange Act.  The undersigned acknowledges that neither the
Company nor the foregoing
attorneys-in-fact assume (i) any liability for the undersigned?s responsibility
to comply with the requirement of
the Exchange Act, (ii) any liability of the undersigned for any failure to
comply with such requirements, or (iii)
any obligation or liability of the undersigned for profit disgorgement under
Section 16(b) of the Exchange Act.
       This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to
file Forms 3, 4, and 5 with respect to the undersigned's holdings of and
transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing
attorneys-in-fact.
       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this
4th day of October, 2017.

/s/ Lewis. C. Cantley Jr.
Signature

Lewis C. Cantley Jr.
Print Name